Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria CH Polman, SC Reingold, B Banwell, M Clanet, JA Cohen, M Filippi, ... Annals of neurology 69 (2), 292-302, 2011 | 11212 | 2011 |
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria AJ Thompson, BL Banwell, F Barkhof, WM Carroll, T Coetzee, G Comi, ... The Lancet Neurology 17 (2), 162-173, 2018 | 7607 | 2018 |
Defining the clinical course of multiple sclerosis: the 2013 revisions FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ... Neurology 83 (3), 278-286, 2014 | 4017 | 2014 |
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis Nature 476 (7359), 214-219, 2011 | 3070 | 2011 |
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis JA Cohen, F Barkhof, G Comi, HP Hartung, BO Khatri, X Montalban, ... New England Journal of Medicine 362 (5), 402-415, 2010 | 2862 | 2010 |
Ocrelizumab versus placebo in primary progressive multiple sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... New england journal of medicine 376 (3), 209-220, 2017 | 2042 | 2017 |
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... New England Journal of Medicine 376 (3), 221-234, 2017 | 1977 | 2017 |
Oral fingolimod (FTY720) for relapsing multiple sclerosis L Kappos, J Antel, G Comi, X Montalban, P O'Connor, CH Polman, T Haas, ... New England Journal of Medicine 355 (11), 1124-1140, 2006 | 1336 | 2006 |
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity R Roxburgh, SR Seaman, T Masterman, AE Hensiek, SJ Sawcer, ... Neurology 64 (7), 1144-1151, 2005 | 1104 | 2005 |
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines M Filippi, MA Rocca, O Ciccarelli, N De Stefano, N Evangelou, L Kappos, ... The Lancet Neurology 15 (3), 292-303, 2016 | 1097 | 2016 |
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 1051 | 2018 |
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes L Kappos, CH Polman, MS Freedman, G Edan, HP Hartung, DH Miller, ... Neurology 67 (7), 1242-1249, 2006 | 1032 | 2006 |
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility International Multiple Sclerosis Genetics Consortium*†, ANZgene, ... Science 365 (6460), eaav7188, 2019 | 1029 | 2019 |
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis X Montalban, R Gold, AJ Thompson, S Otero-Romero, MP Amato, ... Multiple Sclerosis Journal 24 (2), 96-120, 2018 | 1002 | 2018 |
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis D Miller, F Barkhof, X Montalban, A Thompson, M Filippi The Lancet Neurology 4 (5), 281-288, 2005 | 969 | 2005 |
Differential diagnosis of suspected multiple sclerosis: a consensus approach DH Miller, BG Weinshenker, M Filippi, BL Banwell, JA Cohen, ... Multiple Sclerosis Journal 14 (9), 1157-1174, 2008 | 945 | 2008 |
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind … G Comi, V Martinelli, M Rodegher, L Moiola, O Bajenaru, A Carra, ... The Lancet 374 (9700), 1503-1511, 2009 | 798 | 2009 |
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the … L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ... The Lancet 370 (9585), 389-397, 2007 | 737 | 2007 |
Vitamin D as an early predictor of multiple sclerosis activity and progression A Ascherio, KL Munger, R White, K Köchert, KC Simon, CH Polman, ... JAMA neurology 71 (3), 306-314, 2014 | 712 | 2014 |
Multiple sclerosis: clinical aspects J Oh, A Vidal-Jordana, X Montalban Current opinion in neurology 31 (6), 752-759, 2018 | 702 | 2018 |